However, ongoing uncertainty about who owns the rights to this intellectual property may have contributed to shares slipping12.4% last month,according to S&P Global Market Intelligence . Crisper Therapeutics is one of a small group of new biotech start-ups that are researching CRISPR-Cas9, an approach that could potentially reshape disease caused by genetic mutation.